Arcus Biosciences (NYSE:RCUS) initiated with Buy rating and $22 (150% upside) price target at Mizuho Securities.
Stealth BioTherapeutics (NASDAQ:MITO) initiated with Overweight rating at Cantor Fitzgerald.
Hookipa Pharma (NASDAQ:HOOK) initiated with Buy rating and $15 (93% upside) price target at H.C. Wainwright.
Applied Genetic Technologies (NASDAQ:AGTC) upgraded to Outperform with a $9 (125% upside) price target at BMO. Shares up 14% premarket.
Seattle Genetics (NASDAQ:SGEN) upgraded to Buy with a $100 (38% upside) price target at Goldman Sachs.
Accelerate Diagnostics (NASDAQ:AXDX) downgraded to Underweight with a $16 (22% downside risk) price target at JPMorgan.
Atara Biotherapeutics (NASDAQ:ATRA) downgraded to Sell with a $9 (34% downside risk) price target at Goldman.
Luminex (NASDAQ:LMNX) downgraded to Underweight with a $21 (3% downside risk) price target at JPMorgan. Shares down 4% premarket.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.